BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 55 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $198 | 0.0% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $198 | -3.9% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $206 | +3.5% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $199 | -99.9% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $199,000 | +0.5% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $198,000 | -99.5% | 200,000 | -50.0% | 0.00% | -99.3% |
| Q1 2022 | $40,316,000 | +91.4% | 400,000 | +100.0% | 0.15% | +125.8% |
| Q4 2021 | $21,062,000 | +20348.5% | 200,000 | +100.0% | 0.07% | – |
| Q3 2021 | $103,000 | -50.5% | 100,000 | -50.0% | 0.00% | – |
| Q2 2021 | $208,000 | -49.3% | 200,000 | -50.0% | 0.00% | -100.0% |
| Q1 2021 | $410,000 | -4.7% | 400,000 | 0.0% | 0.00% | – |
| Q4 2020 | $430,000 | +105.7% | 400,000 | +100.0% | 0.00% | -100.0% |
| Q3 2020 | $209,000 | -57.5% | 200,000 | -50.0% | 0.00% | -50.0% |
| Q2 2020 | $492,000 | +16.0% | 400,000 | 0.0% | 0.00% | -33.3% |
| Q4 2019 | $424,000 | – | 400,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 16,732,000 | $16,408,385 | 1.23% |
| SONA ASSET MANAGEMENT (US) LLC | 23,125,000 | $22,451,923 | 0.93% |
| SSI INVESTMENT MANAGEMENT LLC | 8,726,000 | $8,464,220 | 0.69% |
| PFM Health Sciences, LP | 15,000,000 | $14,587,500 | 0.69% |
| RWC Asset Management LLP | 10,000,000 | $9,709,000 | 0.63% |
| Sonora Investment Management Group, LLC | 6,245,000 | $6,108,182 | 0.52% |
| Paloma Partners Management Co | 10,006,000 | $9,733,285 | 0.34% |
| MACKAY SHIELDS LLC | 9,891,000 | $9,594,270 | 0.26% |
| PALISADE CAPITAL MANAGEMENT, LP | 8,704,000 | $8,455,066 | 0.24% |
| Centiva Capital, LP | 10,000,000 | $9,716,288 | 0.21% |